Gene therapy developers can expect less hand-holding from OTAT
Regulatory NewsJoanne S. Eglovitch.jpg.aspx?lang=en-us&width=380&height=573&ext=.jpg)
Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)Clinical TrialsComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy